New AAP Guidelines for RSV Immunoprophylaxis in High-Risk Infants and Children

The American Academy of Pediatrics has tightened its clinical guidance on RSV immunoprophylaxis, expanding the qualifying criteria for second-season monoclonal antibody administration in children aged 8 through 19 months. Infants born preterm before 32 weeks of gestation, along with children carrying hemodynamically significant congenital heart disease or neuromuscular impairment, now formally enter the recommended cohort. It's a meaningful policy shift — but if you've been watching the global trial landscape for pediatric biologics, the update also exposes a stubborn gap between who gets studied and who gets protected.

What the AAP actually changed

The updated policy statement, published in Pediatrics, broadens the high-risk qualifying window for second-season nirsevimab or palivizumab administration. Previously, a narrower subset of children met criteria beyond the first RSV season. Now the Academy explicitly recommends protection for preterm infants under 32 weeks' gestational age and for children with specific cardiopulmonary or neuromuscular comorbidities — populations where RSV lower respiratory tract disease carries disproportionate morbidity.

In my experience running cohorts that include these subgroups, the clinical logic is sound. Preterm infants with immature airways and children with compromised respiratory mechanics have historically driven the bulk of RSV-related hospitalizations after the neonatal period. Expanding eligibility to cover the second season acknowledges what the adverse-event and efficacy-endpoint data have been showing: a single season of prophylaxis leaves a clinically meaningful window of vulnerability.

Still, the policy inherits a limitation baked into the evidence base itself. The qualifying criteria are only as good as the trial populations that generated the data — and as a parallel analysis makes painfully clear, those populations skew heavily toward a handful of high-income countries.

A 200-fold disparity in trial geography

A cross-sectional review published in Frontiers in Pediatrics examined 1,863 monoclonal antibody clinical trials registered on ClinicalTrials.gov that permitted pediatric enrollment. The numbers are worth sitting with. Only 239 trials — 12.8% — exclusively enrolled pediatric populations. Just 168 trials, roughly 9%, targeted an infectious disease indication. Bacterial, fungal, and neglected tropical diseases were particularly underrepresented.

The geographical concentration is starker still. Trials conducted in high-income countries outnumbered those in low-income countries by more than 200-fold, even though South Asia and sub-Saharan Africa carry higher burdens of the very diseases these antibodies target. Low patient accrual and trial attrition were the most commonly cited reasons for termination — recruitment failures that compound the access problem.

And then there's the transparency gap. Fewer than a third of the reviewed trials had posted results. Only a small fraction made study protocols, statistical analysis plans, or informed consent forms publicly available, despite mandatory disclosure requirements. When I audit a trial dataset, the first thing I look for is whether the endpoints were pre-specified and the analysis plan locked. The absence of that documentation doesn't just frustrate regulators — it makes it harder to assess whether efficacy findings from a high-income cohort are generalizable to the populations most in need.

Why this matters for pediatric immunology practice

The AAP's policy update is operationally useful for clinicians in the US and similar markets. It gives a clearer decision tree for which 8-to-19-month-olds should receive extended RSV prophylaxis. For families navigating a second RSV season with a medically complex infant, that clarity has real value.

But the broader picture demands sobriety. The global evidence base for pediatric monoclonal antibodies remains geographically narrow and disease-selective. When a policy body expands eligibility criteria, it's implicitly extrapolating from trial cohorts that don't represent the global distribution of disease burden. That's not a reason to withhold the recommendation — the pathophysiology and adverse-event profiles are consistent enough across populations — but it is a reason to track post-implementation surveillance data carefully.

What I'll be watching: real-world effectiveness in the newly included comorbidity subgroups, any signals of adverse events that didn't surface in the original trial cohorts, and whether the Frontiers in Pediatrics findings on trial transparency catalyze any structural shifts in how pediatric mAb studies are registered and reported. The 2026 immunization schedule may already be unharmonious, as one outlet put it — but the evidence architecture underneath these recommendations needs considerably more scaffolding before we can call it globally sound.